Real-world outcomes of Finerenone in Primary Aldosteronism

Simple item page
dc.catalogadoraba
dc.contributor.authorUslar, Thomas
dc.contributor.authorSanfuentes, Benjamín
dc.contributor.authorMuñoz, Iván
dc.contributor.authorAnand Vaidya
dc.contributor.authorBaudrand Biggs, René
dc.date.accessioned2025-06-04T22:09:20Z
dc.date.available2025-06-04T22:09:20Z
dc.date.issued2025
dc.description.abstractPrimary aldosteronism (PA) treatment with mineralocorticoid receptor antagonists (MRAs) is effective but limited by side-effects and low potency of currently available options. Finerenone, a novel MRA, has emerged as a promising alternative but data in PA are lacking. This report presents a real-world study wherein PA patients on eplerenone were forced to switch to finerenone therapy during a national shortage. During treatment with finerenone, blood pressure and antihypertensive dose remained unchanged, but the proportion of patients with normal blood pressure and complete biochemical response was decreased (P = .004 and P = .008, respectively). The latter was determined by a reduction in direct renin concentration, a biomarker previously associated with increased cardiovascular risk in PA. Although these results could be explained by finerenone's unique pharmacokinetics and mechanism of action, further studies are needed to evaluate longitudinal outcomes associated with these findings and determine its effectiveness in PA treatment.
dc.format.extent4 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1093/ejendo/lvaf099
dc.identifier.eissn1479-683X
dc.identifier.issn0804-4643
dc.identifier.scopusid2-s2.0-105005510954
dc.identifier.urihttps://doi.org/10.1093/ejendo/lvaf099
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/104593
dc.identifier.wosidWOS:001490637000001
dc.information.autorucEscuela de Medicina; Baudrand Biggs, René; 0000-0002-8655-4957; 1024
dc.issue.numero5
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.finalk53
dc.pagina.iniciok50
dc.revistaEuropean Journal of Endocrinology
dc.rightsacceso restringido
dc.subjectFinerenone
dc.subjectPrimary aldosteronism
dc.subjectEndocrine hypertension
dc.subjectCardiovascular risk
dc.subjectMineralocorticoid receptor
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleReal-world outcomes of Finerenone in Primary Aldosteronism
dc.typeartículo
dc.volumen192
sipa.codpersvinculados1024
sipa.trazabilidadORCID;2025-05-19
Files
Collections
Artículos de revistas